MedTrace Logo

Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue

NCT00555841 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2012-08-28

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy.

Conditions

Interventions

DRUG

ALC and Placebo

ALC and Placebo

Sponsors & Collaborators

  • Sigma-Tau Research, Inc.

    lead INDUSTRY

Principal Investigators

  • Carmen Escalante, MD · The University of Texas MD Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555841 on ClinicalTrials.gov